Top Advances of the Year: Ovarian Cancer

Obstetrical & Gynecological Survey Pub Date : 2024-04-01 DOI:10.1097/01.ogx.0001016696.16905.e0

M. Lumish, Elise C. Kohn, William P. Tew

引用次数: 0

Abstract

(Abstracted from Cancer 2024;130:837–845 Although novel systemic therapies have prolonged survival in ovarian cancer, it remains the fifth leading cause of cancer-related death in women. In 2022, data showing an overall survival (OS) benefit from poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) were published after a 7-year follow-up period.

查看原文本刊更多论文

年度最佳进展：卵巢癌

(摘自《癌症》2024;130:837-845 虽然新型系统疗法延长了卵巢癌患者的生存期，但它仍是女性癌症相关死亡的第五大原因。2022年，一项为期7年的随访数据显示，聚（ADP-核糖）聚合酶（PARP）抑制剂（PARPi）可提高总生存率（OS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obstetrical & Gynecological Survey

自引率

0.00%

发文量